(NewsDirect)
By David Willey, Benzinga
Read the latestreport on NanoViricides here .
NanoViricides (NYSE American: NNVC) is a drug development company working on a novelnanomedical treatment. It recently updated the world on the status ofits long-awaited and now active trials into its lead drug candidate,NV-CoV-2.
“NV-CoV-2, the Company’s lead drug candidate for thetreatment of coronavirus infections including COVID and potentiallymany cases of long COVID, has entered human clinical trials initiatedby the Drug Sponsor Karveer Meditech Pvt. Ltd. India, the Company’sLicensee and co-developer in India,” announced the Company.
NanoViricides isdeveloping cutting-edge nanomedicine treatments, which use theirspecial nanomicelles’ ability to directly attack and destroy thevirus particles. To do this, the nanoviricides mimick the receptorsite on the cell to which the virus binds. No matter how many variantsdevelop, this site remains the same, so the virus is unlikely toescape the nanoviricide drug.
TheCompany’s drug candidate NV-CoV-2 uses the company’s patentednanoviricide platform technology, which uses novel mechanisms to fightCOVID-19 and potentially all other human coronaviruses.
TheNeed For A Lasting Coronavirus Treatment
As the company races to develop its leadingdrug, there remains asignificant need to develop safe and lasting treatments forCOVID-19 and other coronaviruses.
It has been estimated that by the end of thefour-year period from January 2020 to December 2023, the COVID-19pandemic will have cost the American economy upto $14 trillion .
Furthermore,it is estimated that 65million people still suffer from “long COVID ,” thecontinuation of coronavirus symptoms for months after clinically theinfection itself has subsided. Symptoms of long Covid can range frommild to severe, and the case numbers of those with long Covid arecontinuing to increase.
Could NV-CoV-2 Be Used For FuturePandemics?
Thenthere are the risks of other coronaviruses and future pandemics. Aprediction from the disease research group Metabiota , says that thereis a 47% - 57% likelihood that another pandemic as serious asCOVID-19 could occur within the next 25 years.
This is whyNanoViricides believes it is important to develop a drug thatis safe and effective for treating a wide range of patients .Its drug candidate NV-CoV-2 has oral formulations for milder cases andan injectable solution for more severe patients. The company isfocusing its attention on treatment for COVID-19 for now, but theinnovative nanomedicine could even be a broad-spectrum antiviral fortreating diseases beyond COVID-19.
“We believe these clinical trials are animportant milestone not only for NanoViricides and Karveer Meditech,India, but also for the advancement of treatments against all viralinfections worldwide,” said Dr. Anil Diwan, Ph.D., President andExecutive Chairman of the Company, explaining, “NV-CoV-2 is aimed atsatisfying the as-yet-unmet medical need of a highly effectivebroad-spectrum, anti-coronavirus drug that can be used for all patientpopulations. Moreover, it brings into the clinic a novel platformtechnology of attacking viruses to develop highly effective antiviraldrugs.”
Treatments for COVID-19 currently on the market includeMolnupiravir from Merck & Co. (NYSE: MRK), Paxlovid from Pfizer Inc. (NYSE: PFE) and Remdesivir from Gilead Sciences,Inc . (NASDAQ: GILD), though there are problems or limitations witheach of these options, and the multi-billion-dollar market remainswide open for a new effective treatment. The overall antiviral marketis projectedto surpass around $71.1 billion by 2032 .
Learn more about how NanoViricides is tackling coronaviruses byvisiting its website .
AboutNanoViricides
NanoViricides, Inc. (the "Company")(www.nanoviricides.com) is a development stage company that iscreating special purpose nanomaterials for antiviral therapy. TheCompany's novel nanoviricide® class of drug candidates aredesigned to specifically attack enveloped virus particles and todismantle them. Our lead drug candidate is NV-HHV-101 with its firstindication as dermal topical cream for the treatment of shingles rash.In addition, we are developing a clinical candidate for the treatmentof COVID-19 disease caused by SARS-CoV-2 coronavirus. The Companycannot project an exact date for filing an IND for this drug becauseof its dependence on a number of external collaborators andconsultants.The Company is now working on tasks for completing an INDapplication. The Company is currently pursuing two separate drugcandidates for the treatment of COVID-19 patients. NV-CoV-2 is ournanoviricide drug candidate that does not encapsulate Remdesivir.NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2with Remdesivir encapsulated in it. The Company believes that sinceRemdesivir is already US FDA approved, our drug candidateencapsulating Remdesivir is likely to be an approvable drug, if safetyis comparable. Remdesivir is developed by Gilead. The Company hasdeveloped both of its own drug candidates NV-CoV-2 and NV-CoV-2-Rindependently.The Company intends to re-engage into an IND applicationto the US FDA for NV-HHV-101 drug candidate for the treatment ofshingles once its COVID-19 project moves into clinical trials, basedon resources availability. The NV-HHV-101 program was slowed downbecause of the effects of recent COVID-19 restrictions, andre-prioritization for COVID-19 drug development work.The Company isalso developing drugs against a number of viral diseases includingoral and genital Herpes, viral diseases of the eye including EKC andherpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza,HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.NanoViricides' platform technology and programs are based on theTheraCour® nanomedicine technology of TheraCour, which TheraCourlicenses from AllExcel. NanoViricides holds a worldwide exclusiveperpetual license to this technology for several drugs with specifictargeting mechanisms in perpetuity for the treatment of the followinghuman viral diseases: Human Immunodeficiency Virus (HIV/AIDS),Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, HerpesSimplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV),Influenza and Asian Bird Flu Virus, Dengue viruses, JapaneseEncephalitis virus, West Nile Virus, Ebola/Marburg viruses, andcertain Coronaviruses. The Company intends to obtain a license forpoxviruses if the initial research is successful. The Company'stechnology is based on broad, exclusive, sub-licensable, fieldlicenses to drugs developed in these areas from TheraCour Pharma, Inc.The Company's business model is based on licensing technology fromTheraCour Pharma Inc. for specific application verticals of specificviruses, as established at its foundation in 2005.
Thispost contains sponsored advertising content. This content is forinformational purposes only and not intended to be investingadvice.
Contact Details
NanoViricides,Inc.
+1 203-937-6137
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.